NETS1HD:用于确定先天性巨结肠治疗整体成功的核心结局集开发研究方案
该研究方案拟通过三阶段在线德尔菲法(分别由新生儿专家组、非新生儿专家组和患者/照护者专家组平行参与)对系统综述已识别的结局指标进行评分,并在第三轮后召开40名专家的面对面共识会议,以确定先天性巨结肠治疗研究的核心结局集。核心结局集将定义为共识会议上超过70%的参与者评分为7-9分且少于15%评分为1-3分的结局指标。
要点
- 采用三阶段在线德尔菲法,由新生儿、非新生儿和患者/照护者三个专家组平行评分。
- 第三轮后邀请40名专家参加面对面共识会议,对结局指标重新评分。
- 核心结局集纳入标准为共识会议上超过70%参与者评7-9分且少于15%评1-3分。
核心结论
- 开发核心结局集将有助于减少先天性巨结肠研究中结局指标报告的异质性,从而提高研究质量并最终改善患儿照护。
研究设计与样本
- 研究方案为三阶段在线德尔菲法,由新生儿专家组、非新生儿专家组和患者/照护者专家组三个专家组平行参与;候选结局指标通过系统综述识别。
- 德尔菲第三轮后邀请40名专家参加面对面共识会议,参与者以目的性抽样方式邀请以平衡不同专家组。
主要发现
- 第一轮专家根据各结局指标在确定其/其孩子/其患者先天性巨结肠治疗整体成功中的重要性,对系统综述识别的结局指标按1至9分进行评分。
- 第二轮向专家展示相同结局指标列表及其所在专家组第一轮评分的图示,要求专家在考虑本组其他成员重要性评分后重新评分。
- 第三轮再次要求专家重新评分,并提供全部三个专家组的评分分布图示供参考。
- 共识会议讨论德尔菲过程结果并重新评分结局指标。
关键数值与推荐
- 核心结局集纳入标准:共识会议上超过70%的参与者评分为7-9分且少于15%的参与者评分为1-3分的结局指标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Use of core outcome sets in research has been proposed as a method for countering the problems caused by heterogeneity of outcome measure reporting. Heterogeneity of outcome measure reporting occurs in Hirschsprung's disease (HD) research and is limiting the development of a robust evidence base to support clinical practice. METHODS: Candidate outcome measures have been identified through a systematic review. These outcome measures will form the starting point for a three-phase online Delphi process to be carried out in parallel by three panels of experts. Panel 1 is a neonatal panel; panel 2 is a non-neonatal panel; and panel 3 is a lay panel. In round 1, experts will be asked to score the previously identified outcome measures from 1 to 9 based on how important they think the measures are in determining the overall success of their/their child's/their patient's HD. In round 2, experts will be presented with the same list of outcome measures and graphical representations of how their panel scored that outcome in round 1. They will be asked to re-score the outcome measure, taking into account how important other members of their panel felt it to be. In round 3, experts will again be asked to re-score each outcome measure, but this time they will receive a graphical representation of the distribution of scores from all three panels, which they should take into account when re-scoring. Following round 3 of the Delphi process, 40 experts will be invited to attend a face-to-face consensus meeting. Participants will be invited in a purposive manner to obtain balance between the different panels. Results of the Delphi process will be discussed, and outcomes will be re-scored. Outcome measures where >70% of participants at the meeting scored it 7-9 and <15% scored it 1-3 will form the core outcome set. DISCUSSION: Development of a core outcome set will help to reduce heterogeneity of outcome measure reporting in HD. This will increase the quality of research taking place and ultimately improve care provided to infants with HD.
引用
- Allin B, Bradnock T, Kenny S, et al. NETS1HD: study protocol for development of a core outcome set for use in determining the overall success of Hirschsprung's disease treatment. Trials. 2016. PMID: 27923407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。